Superworth

IQVIA forward PE IQV

Share price divided by analysts' consensus earnings for the next twelve months, since 2013.

Today, Oct 23, 2026
20.5×
10-year median
20.6×
Against its 10-year history
49th
percentile: 0 is its lowest day, 100 its highest
10-year range
11.4× to 29.3×
Peer median
29.2×

IQVIA's forward PE is 20.5× as of Oct 23, 2026.

That is below its ten-year median of 20.6×, close to the middle of its last ten years.

Over that time it ranged from 11.4× in May 2025 to 29.3× in Dec 2021.

The median for 10 diagnostics and research stocks of a similar size is 29.2×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far20.5×12.4×20.5×
202518.2×11.4×18.4×
202417.3×16.8×23.4×
202321.6×17.4×23.7×
202220.5×17.4×26.7×
202129.3×22.0×29.3×
202022.2×15.1×28.0×
201926.7×19.1×27.4×
201818.9×18.0×22.4×
201719.5×17.9×21.7×
201618.9×16.3×20.7×
201519.5×18.1×25.9×
201423.1×18.6×23.1×
201320.6×18.7×23.2×

Against its peers

Companies in Medical - Diagnostics & Research nearest IQVIA's size, closest first, today.

CompanyForward PE
IQVIQVIA20.5×
WATWaters29.2×
IDXXIDEXX Laboratories35.9×
AAgilent Technologies26.4×
ILMNIllumina47.2×
MTDMettler-Toledo International33.9×
DGXQuest Diagnosticsn/m
LHLabcorp17.4×
MEDPMedpacen/m
RVTYRevvityn/m
DHRDanaher25.4×
Peer median29.2×

Where IQVIA ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on IQVIA

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.